Azelnidipine is a novel dihydropyridinetype calcium antagonist with long-acting anti-hypertensive action and a low reported incidence of tachycardia. We aimed to evaluate its antioxidant activity in cultured human arterial endothelial cells under oxidative stress. Endothelial cells were exposed to 1 mM H 2 O 2 and treated with 100 µM a-tocopherol, 1 nM, 10 nM or 100 nM azelnidipine, 100 nM nifedipine or 100 nM amlodipine. After 3 h, the cell number and level of lipid peroxidation were evaluated by measuring the total protein and 8-iso-PGF 2a concentrations, respectively. The total protein concentration was similar with each treatment. Inhibition of 8-iso-PGF 2a was greatest with 10 nM azelnidipine (compared with the other drugs); the difference between 10 nM and 100 nM azelnidipine was not significant. We conclude that azelnidipine has a potent antioxidative effect that could be of significant clinical benefit when combined with its long-lasting anti-hypertensive action and low incidence of tachycardia.
Introduction
Dihydropyridine-type calcium antagonists are commonly used as anti-angina and antihypertensive agents. The dihydropyridines isradipine and lacidipine reportedly have anti-atherogenic potency independent of calcium entry blockade. 1 Jackson et al. 2 demonstrated an anti-atherogenic action of nifedipine in balloon-injury model rats, and showed that such action results from early inhibition of smooth muscle cell proliferation. Amlodipine, another dihydropyridine-type calcium antagonist, has been shown to have potent lipid antioxidant effects, 3 and antioxidative activity has also been suggested as a possible anti-atherogenic mechanism for dihydropyridines. 4 Azelnidipine was developed as a dihydropyridine calcium blocker. It has a gradual, long-lasting anti-hypertensive action and a low incidence of tachycardia, 5 a known complication of this drug class.
Isoprostanes are a series of bioactive prostaglandin (PG) F 2 -like compounds. They are produced from arachidonic acid by a non-enzymatic process, lipid peroxidation, catalysed by oxygen free radicals either on cell membranes or low-density lipoprotein particles. 6 -8 8-Iso-PGF 2α is of particular importance in inducing vasoconstriction 9 and stimulating vascular smooth muscle cell proliferation. 10, 11 Enhanced in vivo production of F 2 -isoprostanes has been reported in several clinical conditions related to oxidative stress, such as ageing, smoking 12, 13 and coronary ischaemia/reperfusion. 14, 15 Measuring the concentration of 8-iso-PGF 2α in cells can be used to assess the antioxidative activity of a drug. 14, 16 We aimed to evaluate the antioxidant activity of azelnidipine compared with nifedipine, amlodipine and α-tocopherol (which also has well-documented antioxidant activity) by investigating the reaction to these agents of cultured human arterial endothelial cells under oxidative stress.
Methods

HUMAN ARTERIAL ENDOTHELIAL CELL CULTURE
Human arterial endothelial cells (1 × 10 5 cells) were cultured in Dulbecco's modified Eagle's medium with 10% fetal calf serum, trypsin, versine, 50 U/ml penicillin and 50 µg/ml streptomycin (all reagents purchased from GIBCO Lab., Gaithersburg, MD, USA). Cells were grown at 37 ºC in a mixture of atmospheric air and 5% CO 2 , and sub-cultured after treatment with 0.25% trypsin and 0.02% EDTA. Sub-confluent endothelial cells, between the 4th and 8th passages, were used for the experiments.
DRUG TREATMENT AND MEASUREMENT OF PROTEIN CONCENTRATION
After 3 -6 h of endothelial cell seeding in three 6-well microplates (Becton Dickinson, Rockville, MD, USA) at 37 ºC, the medium was replaced with medium containing 1 mM H 2 O 2 to induce oxidative stress. Azelnidipine at three different concentrations (1 nM, 10 nM or 100 nM), 100 µM α-tocopherol, 100 nM nifedipine or 100 nM amlodipine was added to one well of each 6-well microplate. Medium containing 1 mM H 2 O 2 only was added to another three microplates (H 2 O 2 alone plates). Control microplates contained no replacement H 2 O 2 medium or any additional reagents. After a further 3 h, incubation at 37 ºC, 8-iso-PGF 2α was measured. The total protein concentration in relation to the number of endothelial cells was measured for each plate using the Bio-Rad protein assay (Bio-Rad, Tokyo, Japan).
8-ISO-PROSTAGLANDIN F 2a MEASUREMENT
The release of 8-iso-PGF 2α from arterial endothelial cells was measured in cultured arterial endothelial cell suspensions. Cells were hydrolysed with 1.5 ml 15% KOH at 40 ºC for 1 h, then the pH was adjusted to 3.0 with HCl. The acidified suspensions were loaded onto a Sep-Pak C18 column (Waters Associates, Milford, MA) pre-conditioned with 5 ml methanol followed by 10 ml HCl (pH 3.0). The column was washed consecutively with 10 ml HCl (pH 3.0) and 10 ml heptane before eluting the sample onto 1 g of Na 2 SO 4 in a glass test tube using a 10 ml mixture of heptane and ethyl acetate (1:1). The sample was then loaded onto a Sep-Pak Silica column (Waters Associates) pre-conditioned with 5 ml methanol followed by 10 ml ethyl acetate. The column was washed with 10 ml ethyl acetate and the sample eluted with a 10 ml mixture of methanol and ethyl acetate (1:1). The eluted sample was dried under nitrogen and reconstituted with assay buffer for the 8-isoprostane enzyme immunoassay (Cayman Chemical Co., Ann Arbor, MI, USA). The enzyme immunoassay was used to measure the concentration of 8-iso-PGF 2α in the sample. 16 
STATISTICAL ANALYSIS
The statistical significance of observed differences in the results was evaluated by unpaired analysis of variance. Probability values were calculated using Scheffe's method. All values are expressed as means ± SD and P < 0.05 was considered significant.
Results
The total protein concentration in each plate is shown in Table 1 and there were no significant differences between plates. The total 8-iso-PGF 2α concentration in each plate is shown in Fig. 1 .
Discussion
By measuring the 8-iso-PGF 2α concentration (8-iso-PGF 2α is an F 2 -isoprostane) we determined that H 2 O 2 induces membrane lipid peroxidation in human arterial endothelial cells. In similar experiments using renal tubular epithelial cells, Salahudeen et al. 17 demonstrated that approximately 100 pg/well F 2 -isoprostane was induced with 0.5 mM H 2 O 2 and that this increased 6-fold with 1.5 mM H 2 O 2 . Furthermore, the potent lipid peroxidation inhibitor 21-aministeroid inhibited F 2 -isoprostane production and attenuated cytolysis, suggesting that membrane peroxidation is one of the mechanisms involved in cell injury.
Dihydropyridines have been reported to display antioxidant activity, 4, 18, 19 and our study examined whether this is the case for azelnidipine. Antioxidant activity, expressed as a decrease in 8-iso-PGF 2α concentration, was demonstrated with azelnidipine at a concentration of 10 nM. In a randomized, double-blind, placebo-controlled trial, Arita et al. 20 showed that the plasma concentration of azelnidipine after 4 weeks' oral administration of 8 mg/day (the established clinical dose) was 13.0 ± 7.8 ng/ml (22.1 ± 13.3 nM), suggesting that this dose of azelnidipine maintains plasma concentrations of ≥ 10 nM. In our study, 10 nM azeldipine is closest to the clinical dose, and suppressed the 8-iso-PGF 2α concentration to approximately 40% of that observed without azelnidipine incubation (the H 2 O 2 only sample). The antioxidant effect of 10 nM azelnidipine was significantly greater than with 1 nM, and those of 10 nM and 100 nM azelnidipine were not significantly different. Mak et al. 18 
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against sarcolemmal lipid peroxidation. As the mechanism of azelnidipine's antioxidant effects was examined in Mak et al.'s study but not ours, the difference in dosedependency between the two experiments may be due to methodological differences, the production of hyperoxidant conditions or the cells used (ventricular myocytes versus endothelial cells). The serum concentrations obtained with daily clinical doses of nifedipine (20 mg orally) and amlodipine (10 mg orally) are 180.7 nM and 10.4 nM, respectively. 21, 22 (The fluid concentration of nifedipine in our study was based on the serum concentration after oral administration.) We therefore compared nifedipine's antioxidant activity with that of azelnidipine at both 10 nM and 100 nM (i.e., at the clinical level and at the same level as nifedipine, respectively). For amlodipine, we used a concentration that was much higher (100 nM) than that produced by the clinical dose (approximately 10 nM) to investigate its effect. Our results show that using concentrations similar to the clinical dose, the antioxidant activity of azelnidipine is superior to the other drugs tested. The concentrations of the drugs used in our study are all equally effective at lowering blood pressure. Yao et al. 19 examined the antioxidant activities in rat brain homogenates of nine calcium antagonists and found the relative order of antioxidant potency to be nifedipine > barnidipine > benidipine > nocardipine > amlodipine > nilvadipine > nitrendipine, with little inhibitory effect shown by diltiazem and verapamil. This suggests that azelnidipine is a highly potent antioxidant among the calcium antagonists.
Mason et al. 3 evaluated the neuroprotective effects of several voltage-sensitive In their experiments using cerebellar granule cell preparations, amlodipine was the most potent inhibitor of neuronal apoptosis (by limiting oxidative damage). The authors concluded that the electron-rich aromatic ring of amlodipine is highly characteristic of a 'chain-breaking' antioxidant. In our study, amlodipine had a weaker antioxidant effect than nifedipine; the difference in results between the two studies is probably due to differences in the experimental conditions. Each dihydropyridine contains an aromatic ring that is an important factor regulating its antioxidant activity. The molecular structure of azelnidipine or the electron-rich aromatic rings produced by oxidation of the dihydropyridine ring 23 are able to trap free radicals. We believe that the potent antioxidative activity of azelnidipine is attributable to these structural characteristics. Cytolysis could be induced by treatment with H 2 O 2 or a high concentration of calcium antagonist and affects the measurement of 8-iso-PGF 2α concentration. We therefore measured the total protein concentration in each microplate well, as it corresponds to the number of cultured cells. Our results revealed no alteration in total protein concentration, indicating that the cell count in each microplate well was similar and did not affect the 8-iso-PGF 2α concentration.
In conclusion, azelnidipine exhibits potent antioxidative activity at its clinical dose. This could be of significant clinical benefit when combined with its long-lasting anti-hypertensive activity and low incidence of tachycardia. 
